Get the Stockscreener App
18.18
1.04%
-0.2486
Neurogene Inc stock is traded at $18.18, with a volume of 329.63K.
It is down -1.04% in the last 24 hours and down -10.06% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$18.43
Open:
$18.33
24h Volume:
329.63K
Relative Volume:
1.41
Market Cap:
$282.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-17.51%
1M Performance:
-10.06%
6M Performance:
-9.21%
1Y Performance:
-21.11%
1-Day Range:
$18.13
$19.23
1-Week Range:
$18.13
$22.99
52-Week Range:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
18.21 | 285.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan
Pullback Watch: Is Neurogene Inc stock a good choice for value investorsJuly 2025 Retail & AI Enhanced Trading Signals - moha.gov.vn
Breakout Move: How Applied Industrial Technologies Inc AT4 stock reacts to monetary easingTrend Reversal & Safe Swing Trade Setup Alerts - moha.gov.vn
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation - Sahm
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
What catalysts could drive Neurogene Inc. stock higherPortfolio Diversification Tips & Free Hedging Tactics for Volatile Markets - bollywoodhelpline.com
Sell Signal: Is Neurogene Inc stock gaining market shareJuly 2025 Sentiment & Low Risk High Reward Ideas - moha.gov.vn
Earnings Beat: Is Neurogene Inc stock a good choice for value investorsQuarterly Portfolio Summary & Verified Entry Point Signals - moha.gov.vn
Will Neurogene Inc. stock benefit from upcoming earnings reportsWeekly Profit Report & Low Risk Entry Point Tips - Улправда
Why Neurogene Inc. stock appeals to dividend seekersQuarterly Profit Summary & Weekly Breakout Watchlists - Улправда
Will Neurogene Inc. stock gain from lower inflationWeekly Trade Report & Daily Price Action Insights - DonanımHaber
Is Neurogene Inc. stock gaining market shareJuly 2025 Chart Watch & AI Optimized Trade Strategies - DonanımHaber
Can Neurogene Inc. stock continue upward trend2025 Key Highlights & Expert Verified Movement Alerts - DonanımHaber
Will Neurogene Inc. stock split again soonJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
Will Neurogene Inc. (UU8) stock benefit from Fed rate cutsRecession Risk & AI Powered Market Entry Ideas - DonanımHaber
Momentum Shift: Why Neurogene Inc. stock appeals to dividend seekersWeekly Trade Summary & Weekly High Return Opportunities - Улправда
Can Neurogene Inc. stock maintain operating marginsMarket Risk Report & Precise Trade Entry Recommendations - ulpravda.ru
Can Neurogene Inc. stock deliver surprise earnings beatWeekly Earnings Recap & Risk Managed Trade Strategies - Улправда
Insider Buy: Why Neurogene Inc. stock appeals to dividend seekersQuarterly Portfolio Report & Advanced Technical Analysis Signals - Улправда
Neurogene (NASDAQ:NGNE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Contrasting Neurogene (NASDAQ:NGNE) & Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Entry Recap: Why Neurogene Inc stock appeals to dividend seekersMarket Trend Summary & Reliable Trade Execution Plans - moha.gov.vn
How Neurogene Inc. stock reacts to job market dataMarket Sentiment Report & Safe Swing Trade Setups - Newser
Will Neurogene Inc. (UU8) stock rise with strong economyEarnings Growth Summary & Weekly Market Pulse Updates - Newser
Will Neurogene Inc. (UU8) stock keep high P E multiplesCPI Data & Low Volatility Stock Recommendations - Newser
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene (Nasdaq: NGNE) approves inducement stock options for 4,860 shares - Stock Titan
Swing Trade: Can Neurogene Inc stock deliver surprise earnings beatJuly 2025 Retail & Weekly High Momentum Picks - moha.gov.vn
Will Neurogene Inc. (UU8) stock outperform value peers2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Will Neurogene Inc. (UU8) stock profit from automation waveJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Gene therapy NGN-401 leads to functional gains in Rett syndrome - Rett Syndrome News
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Is Neurogene Inc. (UU8) stock safe for risk averse investorsJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Is Neurogene Inc. (UU8) stock inflation resilientQuarterly Performance Summary & Risk Managed Trade Strategies - Newser
How institutional buying supports Neurogene Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - Newser
Will Neurogene Inc. (UU8) stock outperform benchmarksJuly 2025 EndofMonth & Community Consensus Stock Picks - Newser
Neurogene (NGNE) Stock Analysis Report | Financials & Insights - Benzinga
Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Hold" by Brokerages - MarketBeat
How Neurogene Inc. (UU8) stock correlates with oil markets2025 Geopolitical Influence & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Is Neurogene Inc a good long term investmentPortfolio Diversification Tips & Small Budget Wealth Tips - earlytimes.in
Wall Street analysts’ outlook for Neurogene Inc (NGNE) - Setenews
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth - Yahoo Finance
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE) - Seeking Alpha
EBIT per share of Neurogene Inc. – FWB:UU8 - TradingView
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18 - MSN
Neurogene Inc Stock Analysis and ForecastTake Profit Strategies & Start Your Free Trading Journey Today - earlytimes.in
How Neurogene Inc. (UU8) stock reacts to Fed tighteningWeekly Market Outlook & Weekly Chart Analysis and Trade Guides - newser.com
Statistical indicators supporting Neurogene Inc.’s strengthJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Will Neurogene Inc. (UU8) stock beat international competitionMarket Movers & Long-Term Growth Plans - newser.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):